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Summary The assessment of chromosomal mutations in children may provide information about aetiology
and risk of second malignancies. A somatic cell mutation assay which determines variant erythrocytes lacking
expression of an allelic form of the sialoglycoprotein, glycophorin A, was applied to samples from children
before and after receiving potentially genotoxic therapy. Fifty-six children who had received treatment for
their malignancy, 15 with malignancy but prior to treatment and 43 control children were assessed for the
presence of N0 and NN mutant variant red cells. Control children had mean (s.d.) N0 and NN variant
frequencies (Vf) of 9.5 (7.0) and 5.8 (3.3) x 106 erythrocytes respectively. Comparison between pre-treatment
and control groups demonstrated that prior to chemotherapy, patients with paediatric malignancy do not have
mutant frequencies significantly different from the normal population. Children who had received
chemotherapy, with or without radiotherapy, showed a significant elevation of both N0 and NN variants over
10 years from the end of treatment. Exposure of children to radiotherapy or known chemical mutagens leads
to an increased frequency of variant erythrocytes which is probably the result of in vivo somatic cell mutations.
The long term implications have yet to be determined.
The improved survival ofchildren with malignancies over the
last 30 years is clearly the result of more intensive treatment
schedules. Radiotherapy and many chemotherapeutic drugs,
however, are known to be genotoxic and chromosomal
damage in treated patients has been documented (Haglund et
al., 1980; Robison et al., 1982). An increased risk of second
malignancies in treated patients has also been reported (Haw-
kins et al., 1987) and may be related to the increased number
of mutations, although the relationship between mutagenesis
and carcinogenesis remains to be clarified. Survivors ofchild-
hood malignancy have a longer life span than their adult
counterparts and the lifetime risk of second malignancy is
therefore greater. Assessment of chromosomal damage may
help to predict those children at an increased risk of second
malignancy following treatment. Current methods of measur-
ing somatic mutations, such as the HPRT assay, require large
volumes of blood (20 ml) and are therefore difficult to apply
in paediatric practice. The glycoprotein A (GPA) assay
requires small amounts of blood (100pl), provides rapid
results (within 36 h) and does not require immediate prepara-
tion of samples. Consequently it is ideal for assessing muta-
tions in the paediatric population or where samples have to
be transported from peripheral centres. The principles of the
assay have been described previously (Langlois et al., 1990)
but briefly it enumerates variant red cells which have under-
gone phenotypic change of the M and N antigens resident on
the glycoprotein molecule. Heterozygotes, who express both
M and N antigens can be assessed for the absence of one or
other antigen (N0 or M0 variant cells) or their reduplication
(NN or MM variant cells) on some red cells. Fluorescently
labelled monoclonal antibodies are used to visualise these
antigens and a flow cytometer to determine the variant cell
frequency (Vf). This provides an assessment of chromosomal
damage in the erythroid stem cells at the GPA locus -
4q28-q31 (Rahuel et al., 1988). The assay has been applied to
normal adults and the mean variant frequencies established
as N0 = 6.2 and NN = 8.7 per million red cells (Langlois et
al., 1990). Adults with a known increased risk of developing
malignancy have been assessed with the GPA assay sur-
vivors of the atomic bomb (Langlois et al., 1987), individuals
with Bloom's syndrome (Langlois et al., 1989) and ataxia
telangiectasia (Bigbee et al., 1989) - and have been found to
have raised Vfs. Adult patients receiving chemotherapy have
also been studied (Bigbee et al., 1990) and demonstrate Vfs
which rise through treatment, plateau and then fall back into
the normal range. The current study used the GPA assay to
evaluate the genotoxic effects of radiation and chemotherapy
in the paediatric age group.
Materials and methods
Patients andsamples
Samples of blood for both control and study groups were
obtained from children attending the Royal Hospital for Sick
Children, Bristol or regionally supported clinics. Forty-three
children (mean age 6.3 years; range 0.9-16.4 years) attending
the hospital for routine surgery provided control samples. In
15 of the patient group, the samples were obtained before
chemotherapy was started (mean age 5.4 years; range 1.6
- 16.6 years) and these children are referred to as the pre-
treatment group. Fifty-six patients with paediatric malignan-
cies (mean age 13.4 years; range 2.2-32.9 years) provided
samples 1 to 16.5 years after diagnosis. These children, who
were aged 0.93 to 16.58 years at the time of diagnosis,
formed the post-treatment group. No child in this part of the
study provided more than one sample. The study was ap-
proved by the Bristol and Weston Health Authority Ethical
Committee.
The criteria for selection of the patients were that they
were MN phenotypes, that they had not received any blood
product transfusions within the preceding 160 days and that
those in the post-treatment group had received radiotherapy
and chemotherapy containing at least one mutagenic drug.
Children currently receiving intensive courses of chemother-
apy were invariably excluded from the study as they were
usually dependent upon transfused blood products. The chil-
dren who had received treatment had the following maligan-
cies (numbers in parentheses): leukaemia (22), lymphoma
(eight), bone tumours (six), renal tumours (five), rhabdo-
myosarcomas (six), undifferentiated round cell tumours
(four), neuroblastoma (three) and malignant teratoma (one).
The following tumours were found in the children who
formed the pre-treatment group: leukaemia (eight), bone
tumours (two), renal tumours (two), rhabdomyosarcomas
(one), malignant teratoma (one) astrocytoma (one) and mal-
ignant nerve sheath tumour (one). The chemotherapeutic
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drugs included: actinomycin D, asparaginase, doxorubicin,
daunorubicin, epirubicin, bleomycin, etoposide, cyclophos-
phamide, carboplatin, cisplatin, cytosine, ifosfamide, methotrex-
ate, prednisolone, procarbazine, chlorambucil, mercaptopurine,
thioguanine and vincristine. Thirty-six of the 56 patients
received radiotherapy as part of their treatment protocol.
Preparation and assay ofsamples
Samples were collected in EDTA tubes and were stored at
4°C for up to 1 week before being prepared. MN status was
confirmed using commercial anti-M and anti-N typing sera
(Biotest). The method ofpreparing the erythrocytes has been
described (Langlois et al., 1990) but briefly 100ftl of donor
cells are fixed in 10% formalin and made spherical with a
0.005% solution of sodium dodecylsulphate (SDS). The N-
specific antibody, BRIC157, was a gift of Dr D. Anstee,
Blood Group Reference Laboratory, Bristol and was purified
by chromatography over Protein G Sepharose (Pharmacia)
before beign labelled with fluorescein (Sigma) (abbreviated to
BRIC157-). The M-specific antibody, 6A7, was a gift of Dr
R. Jensen, Lawrence Livermore Laboratories, California and
was supplied biotinylated (abbreviated as 6A7b). Both
antibodies are now available from the Commercial Depart-
ment, Blood Products Reference Laboratory, Dagger Lane,
Elstree. London.
Approximately 25 x 106 erythrocytes were incubated with
both antibodies at room temperature for 1 h, washed and
then mixed with streptavidin-phycoerythrin (suffix-PE) (Vecta
Labs, 5il ml1'). Propidium iodide (Sigma, 10llml-') was
later added to exclude any nucleated cells from analysis by
the cytometer. All samples were analysed on a BD Facscan
within 12 h of labelling. Control mixtures of red cells were
used on each run to establish standard gain and compensa-
tion settings and to set the variant cell windows. Cells were
analysed at a rate of 3,000-4,000 per second. Only N0 and
NN variants can be assessed using the BRIC157/6A7 anti-
body combination (Langlois et al., 1990). For each sample,
two runs of 106 cells were analysed and the Vfs (N01, NN1;
N02, NN2) determined by dividing the number of events in
the respective variant cell window by the total number of
events in the flow distribution. Mean N0 and NN values
(mN0 and mNN) were calculated from these two runs. At
least one control was included with each batch of samples
run on the cytometer.
Statistical analysis
The data from the patient samples was not normally dis-
tributed and therefore a non-parametric analysis comparing
the three groups was undertaken with the Kruskall-Wallis
and Mann-Whitney U tests. Samples were grouped according
to time from the end of chemotherapy and comparison with
the control group was undertaken to assess persisting eleva-
tion from the normal range over time. Comparison ofvariant
frequences between patients who had or had not received
radiotherapy was also performed using the Mann-Whitney-U
test.
Results
The mean Vfs (and s.d.) for the control group were N0 9.5
(7.0) and NN 5.8 (3.3) and an example of a scattergram from
one such patient is shown in Figure 1. Linear regression
analysis of the N0 Vfs against age in the control group did
not suggest a positive relationship in this group of children
(data not shown). The results for the three groups, along
with inter-group statistical analyses, are summarised in Table
I.
Both mN0 and mNN variant values were plotted against
time elapsed from the end of chemotherapy (Figures 2 and
3). Variant frequencies rose through the latter parts of some
of the prolonged courses of chemotherapy but then fell
towards normal over the subsequent years. Comparison
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Figure 1 Bivariate scattergram from normal control. Fixed
erythrocytes from the donor are labelled with BRIC157-f (anti-N,
FLI) and 6A7b-PE (anti-M, FL2) and one million events ana-
lysed and shown in the scattergram. Axes represent 64 linear
channels equally distributed over a four decade range of fluores-
cent intensity. The main peak of MN cells has channel co-
ordinates of x = 42 and y = 46.
Table I Summary statistics for the three study groups
Group Median Range PI
No Variants
Control 7 1-31
Pre Treatment 12 3-39 0.10 0.0001
Post Treatment 17 1-281 0.05
NN Variants
Control 6 1-13
Pre Treatment 6 2-24 0.26 0.001
Post Treatment 13 1-71 0.01
Valuesrepresentvariantfrequencies x 106red bloodcells. aMeanVfs
for each donor were used to determine range. bMann Whitney U test.
* Iaa 3G00
X '. * *.
4,4*>04 .* ,,,'*'"**'"'A''*i''"' .. ......*29.j. /
*. . ~ -; Yiiin ; J.:...
Figure 2 Distribution of N0 variant frequencies against time
elapsed from the end of chemotherapy. Dotted line marks the
end of therapy. Vfs for control A, and pre-treatment B, groups
are shown to the left of the dotted line.
between groups of patients and the control group showed
that there was a significant, and clearly, persisting elevation
of both N0 and NN variants over 10 years from from the
end of treatment (P = 0.01 and 0.02 respectively), (Table II).
A detailed assessment of the whole group for the possible
mutagenic effect of individual drugs was not possible due to
the large number, the range of doses and the variety of drug
combinations used. It is hoped, however, that as more
patients are analysed this type of information may become
available.
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Figure 3 Distribution of NN variant frequencies against time
elapsed from the end ofchemotherapy. Annotations as for Figure
2.
TableII Comparison betweencontrol groupandgroups atdesignated
time intervals from the end ofchemotherapy
Comparison with Control
Group Number in Group. PI
Interval Group mNo mNN
Control 43 - -
Pre- 15 0.11 0.26
treatment
On 4 0.003 0.0001
treatment
at time of
sample
0-1 yr 7 0.06 0.02
post-
treatment
1-2 yr 7 0.02 0.001
post-
treatment
2-3 yr 11 0.01 0.0004
post-
treatment
3-5 yr 5 0.06 0.20
post-
treatment
5-10 yr 11 0.03 0.004
post-
treatment
10+yr 11 0.01 0.02
post-
treatment
'Mann Whitney U test.
Comparison of Vfs between those patients who had re-
ceived radiotherapy and those who had not showed no statis-
tical difference between age at diagnosis, age at providing
sample and variant frequency.
Four children provided samples whilst still receiving oral
chemotherapy. All had acute lymphoblastic leukaemia (ALL)
and were being treated on the UK ALL (X) protocol and,
consequently, were receiving maintenance treatment of daily
6-mercaptopurine, weekly methotrexate and thrice weekly
co-trimoxazole (trimethoprim/sulphamethoxazole). Three of
these patients showed very high Vfs on numerous occasions,
with characteristic bivariate scattergrams (Figure 4). This
scattergram pattern was similar to that seen in a patient with
ataxia telangiectasia and a non Hodgkin's lymphoma (Figure
5) who was not included in the main study group.
Discussion
Although the precise relationship between mutagenesis and
carcinogenesis remains unclear there is much circumstantial
Figure 4 Bivariate scattergram from patient with high Vfs.
Labelling details as for Figure 1. In this sample there is a tail of
partially labelled variants extending from the main MN peak
down to the N0 variant window. There is also a small tail
running parallel to the x-axis from the MN peak which would
represent partially labelled M0 variants. The patient consistently
produced this pattern with repeated analysis. He relapsed on
treatment and died shortly afterwards.
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Figure 5 Bivariate scattergram of patient with ataxia telangiec-
tasia. This sample from a 10 year old boy with ataxia telangiec-
tasia shows two long tails of variant erythrocytes arising from the
main MN peak and running towards the N0 and M0 variant
windows. These patients have very high variant cell frequencies.
evidence to support the two are related (Sikora, 1990).
Assessment of mutations, therefore, may help clarify aeti-
ological factors in the development of tumours.
The outlook for children with malignancy has improved
substantially but the risk of developing second tumours has
also become significant. It is likely that this increased inci-
dence is related to the use of radiation and high dose
chemotherapy during the primary treatment and is presum-
ably mediated through the induction of mutations. Monitor-
ing mutations in the years after treatment may help to clarify
this point and determine'those children at increased risk of
further malignancies.
Like most other methods for assessing chromosomal muta-
tions, the GPA assay looks specifically at alterations in pro-
tein expression at one particular genetic locus and from this,
the likelihood of generalised DNA damage is extrapolated.
Clearly such generalised damage may not have occurred in
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all patients since isolated mutations, involving only a few
base pairs, could be responsible for the malignant change in
some cases.
In the current study, the GPA assay showed mutation
frequencies for a group of normal children of around nine
N0 variants and six NN variants per million red cells. These
values are similar to those determined by the GPA assay
(Langlois et al., 1990) and the HPRT assay (O'Neill et al.,
1989) in normal adults. The origin of N0 variants is likely to
be deletion mutations involving the GPA locus on chromo-
some 4 whereas the homozygous variants, NN, probably
arise by chromosomal missegregation or mitotic recombina-
tion (Cavenee et al., 1983). Both of the latter events are
independent of the deletions which give rise to the hemi-
zygous variants. Consequently the determination of both
variants may ultimately provide information on different
mechanisms on DNA damage.
Comparison of the pre-treatment group with controls dem-
onstrates that before exposure to chemotherapy most
patients with paediatric malignancy do not have mutant
frequencies different from the normal population. This im-
plies that they are neither more prone to spontaneous muta-
tions nor have they been exposed to any obvious mutagens.
This has also been established in adults by others (Bigbee et
al., 1990; Dempsey et al., 1985).
It is recognised that chromosomal mutation frequencies
increase with age (Cole et al., 1989) and the current study
does have an age imbalance between the control and treat-
ment groups which arose from ethical constraints of obtain-
ing blood from normal children. One has to consider the
possibility that the observed differences in variant frequencies
between these groups simply reflects a difference in age com-
position between the groups. Analysis of the data, however,
showed this not to be the case, as Vfs from control patients
did not demonstrate a positive relationship with age and the
high Vfs seen in many of the post treatment groups lay well
outside the expected range suggested by Jensen et al. (Jensen
et al., 1987).
Analysis of the post-treatment group demonstrates that
exposure to radiotherapy or known chemical mutagens leads
to an increased frequency of variant erythrocytes which are
presumably the result of in vivo somatic cell mutations. This
finding confirms those in other studies which have looked at
chemotherapy induced mutations using both the GPA and
the HPRT assays (Bigbee et al., 1990; Dempsey et al., 1985)
in adults.
The plot of Vfs against time from end of chemotherapy
demonstrates that the induced high levels of mutations even-
tually fall back towards normal. This decay, however, is
protracted and well beyond the lifespan of circulating red
cells suggesting that some mutations at the GPA locus have
been stably incorporated into the erythroid stem cells. The
elevations persisted over 10 years from the end of treatment
which seems at variance with the report of Bigbee et al.,
where the high Vfs induced by chemotherapy in adults fell
back to the normal range within 6 months (Bigbee et al.,
1990).
Persistently elevated Vfs have been reported in adults after
exposure to high doses of radiation (Langlois et al., 1987)
but comparison of Vfs between those children who had
received radiotherapy and those who had not failed to show
a significant difference between the two. An alternative ex-
planation is that these childhood patients received substan-
tially more intensive chemotherapy than the adults previously
reported.
If the evolution of cancers is due to chromosomal muta-
tions, then the persistence of such induced mutations many
years after the end of chemotherapy may have implications
for the development of second malignancies. Further long
term studies, however, are necessary to determine whether
the increase in mutation frequency is of any value in predic-
ting which patients develop second tumours.
The grossly elevated Vfs observed in three of the four
children who provided samples whilst still receiving chemo-
therapy merits further investigation. Clearly the number of
patients is small but the bivariate scattergram which was
observed was most striking. The long tail of cells from the
main peak to the hemizygous variant loss window was
repeated in all three of the high count patients. These cells
with partial loss variants have been observed before (Langois
et al., 1989; Kyoizumi et al., 1989). Obviously this pattern
could be artefactual and might represent interference with the
attachment of the monoclonals by drug metabolites. If this
was the case, however, one would expect all four patients
receiving the same chemotherapy to demonstrate the same
pattern. Furthermore, a generalised disruption in antibody
attachment would lead to diffuse distribution of cells on the
bivariate scattergram. In this small group of patients, the
partial loss variants are expressing normal amounts of the N
antigen and a range of M antigen, from complete expression
(i.e. MN cells) to complete absence (i.e. N0 cells). The
bivariate pattern seen is similar to that produced in patients
with known DNA repair defect syndromes such as ataxia
telangiectasia (Figure 5) and Bloom's syndrome. Affected
patients with both these conditions are susceptible to chemo-
therapy/radiotherapy induced DNA damage. The three pa-
tients presented here may have an increased tendency to
chromosomal mutation or a decreased ability to repair DNA
defects and this may have some bearing on the fact that two
of the three patients with very high Vfs have relapsed either
on treatment or shortly after. Clearly more detailed investiga-
tion of such patients is needed.
The patients in this study had a heterogeneous group of
malignancies and consequently received a wide variety of
chemotherapeutic agents. This must obviously influence the
interpretation of the comparative data. The study does, how-
ever, show that chemotherapy with or without radiotherapy
given to children with malignant disease leads to DNA muta-
tions. In some patients these mutations persist for many
years after the end of treatment and this may influence the
long term prognosis.
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